Literature DB >> 2521417

Regression of left ventricular mass is accompanied by improvement in rapid left ventricular filling following antihypertensive therapy with metoprolol.

W B White1, P Schulman, M K Karimeddini, V E Smith.   

Abstract

Left ventricular hypertrophy is associated with abnormal left ventricular diastolic filling in patients with hypertension. To assess the effects of antihypertensive therapy on the heart in nine previously untreated patients with echocardiographically-detected left ventricular hypertrophy, left ventricular mass and rapid left ventricular filling rate were compared before and after 6 months of treatment with metoprolol monotherapy. Metoprolol was given in doses of 100 to 400 mg/day (average dose, 167 mg/day in two divided doses) and significantly reduced both casual, office blood pressure (150/101 to 130/86 mm Hg, p less than 0.01) and 24-hour ambulatory blood pressure (139/91 to 126/79 mm Hg, p less than 0.05 for systolic, p less than 0.01 for diastolic). Following treatment with metoprolol, left ventricular mass index decreased from 135 +/- 20 to 120 +/- 13 gm/m2 (p less than 0.05), while rapid left ventricular filling rate increased from 1.89 +/- 0.24 to 2.09 +/- 0.27 end-diastolic volumes/sec (p less than 0.01). The reduction in left ventricular mass index was secondary to decreased posterior and septal wall thicknesses (13% and 11%, respectively, p less than 0.05 for both), as there were no changes in the left ventricular internal dimensions. Neither resting nor exercise left ventricular ejection fraction changed on metoprolol therapy compared to the baseline values. These data demonstrate that regression of left ventricular hypertrophy in never-previously-treated hypertensive patients is accompanied by improved diastolic performance following beta-adrenergic blocker monotherapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521417     DOI: 10.1016/0002-8703(89)90669-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

Review 1.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 2.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Ambulatory blood pressure monitoring for the assessment of nicardipine as a third drug in severe essential hypertension.

Authors:  Y Lacourcière; L Poirier; C Lévesque; P Provencher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Left ventricular hypertrophy reversal with labetalol and propranolol: a prospective randomized, double-blind study.

Authors:  J Szlachcic; W D Hall; J F Tubau; V Porter; C Vollmer; G Wollam; A Hirsch; B Massie
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 5.  Diastolic function in hypertension.

Authors:  R A Phillips; J A Diamond
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

6.  Cushing's syndrome: still a potential killing disease.

Authors:  P A Younge; D Shmidt; P G Wiles
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

Review 7.  Hypertension and diastolic function.

Authors:  E Agabiti-Rosei; M L Muiesan
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 8.  Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.

Authors:  C Morisco; L Argenziano; N Tozzi; A F Mele; B Ricciardelli; G Condorelli; B Trimarco
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Effects of bisoprolol on left ventricular hypertrophy in essential hypertension.

Authors:  E de Teresa; M González; C Camacho-Vázquez; M J Tabuenca
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.